Not yet recruiting
Non-small cell lung cancer metastatic
Not yet recruitingStudy on the Safety and Effectiveness of GFH925 and Cetuximab for Patients with Advanced Lung Cancer with KRAS G12C Mutation
Registered drugNo placebo
Study on the Safety and Effectiveness of GFH925 and Cetuximab for Patients with Advanced Lung Cancer with KRAS G12C Mutation
Registered drugNo placebo
- Disease:Non-small cell lung cancer metastatic
- Substances:CetuximabGFH925
Countries:
Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Cetuximab
